semaglutide gastrointestinal obstruction class action in dallas bowel lawyer Zepbound Lawsuit [2026] semaglutide gastric intestinal obstruction law

The MedWatch program of the US Food and Drug Administration (FDA) has not received reports of semaglutide-related safety events, and few studies have characterized skin findings associated with subcutaneous or oral semaglutide, a glucagon-like peptide 1 agonist used for obesity and type 2 diabetes treatment

A peer-reviewed review in Frontiers in Endocrinology summarizing peptide mechanisms and clinical potential for obesity and metabolic dysregulation provides the scientific framework behind this class of treatments

Administered weekly, they offer a convenient and impactful approach to achieving your health goals

Semaglutide is used most often as a diabetes medication

GLP-1 analogs have a similar structure to endogenous GLP-1, mimicking its actions in the pancreas, stomach, and brain